Literature DB >> 35518792

Inverse pityriasis rosea secondary to COVID-19 vaccination.

Blayne Fenner1, Jessica L Marquez2, Meredith Pham3, Michelle Tarbox3.   

Abstract

A 56-year-old woman presented for evaluation of a pruritic rash with associated body aches, fever, and chills that first appeared about 1 week after Johnson and Johnson COVID-19 vaccination. The rash initially presented as one lesion on her left breast that then spread to her face and groin. Based on clinical presentation, dermoscopic findings, and histopathological examination, a diagnosis of inverse pityriasis rosea was made. Although the exact pathogenesis of pityriasis rosea remains unknown, current evidence suggests that the inflammatory reaction to infectious agents, vaccines, certain drugs, or reactivation of herpesvirus 6 and 7 are possible etiologies.
Copyright © 2022 Baylor University Medical Center.

Entities:  

Keywords:  COVID-19; pityriasis rosea; vaccination

Year:  2022        PMID: 35518792      PMCID: PMC9037553          DOI: 10.1080/08998280.2022.2044742

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  10 in total

Review 1.  Vaccine-induced pityriasis rosea and pityriasis rosea-like eruptions: a review of the literature.

Authors:  F Drago; G Ciccarese; S Javor; A Parodi
Journal:  J Eur Acad Dermatol Venereol       Date:  2014-12-29       Impact factor: 6.166

2.  Pityriasis Rosea: Diagnosis and Treatment.

Authors:  Jose M Villalon-Gomez
Journal:  Am Fam Physician       Date:  2018-01-01       Impact factor: 3.292

3.  Unique clinical presentations of pityriasis rosea: aphthous ulcers, vesicles and inverse distribution of lesions.

Authors:  Naeha Gupta; Jacob O Levitt
Journal:  Dermatol Online J       Date:  2017-02-15

Review 4.  Pityriasis rosea-like cutaneous eruption as a possible dermatological manifestation after Oxford-AstraZeneca vaccine: Case report and brief literature review.

Authors:  Maria Cristina Pedrazini; Mariliza Henrique da Silva
Journal:  Dermatol Ther       Date:  2021-09-25       Impact factor: 3.858

Review 5.  Pityriasis rosea.

Authors:  Daniel L Stulberg; Jeff Wolfrey
Journal:  Am Fam Physician       Date:  2004-01-01       Impact factor: 3.292

6.  Pityriasis rosea after mRNA COVID-19 vaccination.

Authors:  Lina Abdullah; Divina Hasbani; Mazen Kurban; Ossama Abbas
Journal:  Int J Dermatol       Date:  2021-06-10       Impact factor: 2.736

7.  Pityriasis rosea, COVID-19 and vaccination: new keys to understand an old acquaintance.

Authors:  J M Busto-Leis; G Servera-Negre; A Mayor-Ibarguren; E Sendagorta-Cudós; M Feito-Rodríguez; A Nuño-González; M D Montero-Vega; P Herranz-Pinto
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-05-12       Impact factor: 9.228

8.  Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases.

Authors:  Devon E McMahon; Erin Amerson; Misha Rosenbach; Jules B Lipoff; Danna Moustafa; Anisha Tyagi; Seemal R Desai; Lars E French; Henry W Lim; Bruce H Thiers; George J Hruza; Kimberly G Blumenthal; Lindy P Fox; Esther E Freeman
Journal:  J Am Acad Dermatol       Date:  2021-04-07       Impact factor: 11.527

9.  SARS-CoV-2 spike protein positivity in pityriasis rosea-like and urticaria-like rashes of COVID-19.

Authors:  E Welsh; J A Cardenas-de la Garza; A Cuellar-Barboza; R Franco-Marquez; R I Arvizu-Rivera
Journal:  Br J Dermatol       Date:  2021-03-04       Impact factor: 11.113

Review 10.  Pityriasis Rosea: An Update on Etiopathogenesis and Management of Difficult Aspects.

Authors:  Khushbu Mahajan; Vineet Relhan; Aditi Kochhar Relhan; Vijay Kumar Garg
Journal:  Indian J Dermatol       Date:  2016 Jul-Aug       Impact factor: 1.494

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.